Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Related Keywords

United States ,San Diego ,California ,Cris Calsada ,Sarah Sutton ,Jay Hagan ,Regulus Therapeutics Inc ,Program Updates ,Rnas The Company Or Regulus ,Nasdaq ,Enterprise Associates ,Development Rd Expenses ,Exchange Commission ,Autosomal Dominant Polycystic Kidney Disease ,Multiple Ascending Dose ,Private Placement ,Federated Hermes Kaufmann Funds ,New Enterprise Associates ,Dominant Polycystic Kidney Disease ,Private Securities Litigation Reform Act ,Relations Contact ,